2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1．本次股东大会未出现否决议案的情形； 2．本次股东大会不涉及变更前次股东大会已通过的决议的情形。 证券代码：301060 证券简称：兰卫医学 公告编号：2024-043 上海兰卫医学检验所股份有限公司 现场会议召开时间：2024 年 9 月 19 日（星期四）下午 14:00。 网络投票时间：2024 年 9 月 19 日（星期四）。其中 2．现场会议召开地点：上海市长宁区临新路 268 弄 1 号楼兰卫医学 6 楼会议室。 3．会议召开方式：采取现场投票与网络投票相结合的方式召开。 4．会议召集人：公司董事会。 5．会议主持人：公司董事长曾伟雄先生。 6．本次股东大会的召集、召开与表决程序符合有关法律、行政法规、部门规章、 规范性文件及《上海兰卫医学检验所股份有限公司章程》的有关规定。 7．会议出席情况 股东出席的总体情况： 通过现场和网络投票的股东 219 人，代表股份 247,881,075 股，占上市公司有表决 权股份总数（已剔除截至股权登记日公司回购 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2024-042 上海兰卫医学检验所股份有限公司 首次公开发行前已发行股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为上海兰卫医学检验所股份有限公司（以下简称"公司" 或"发行人"）首次公开发行前已发行股份。本次解除限售并上市流通的股份数量为 216,673,308 股，占公司股本总数的 54.10%，锁定期为自公司首次公开发行并上市之日 起 36 个月。 2、本次解除限售股份上市流通日期为 2024 年 9 月 13 日（星期五）。 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意上海兰卫医学检验所股份有限公司首次公开 发行股票注册的批复》（证监许可〔2021〕2503 号）同意注册，公司向社会公众公开发 行人民币普通股（A 股）股票 48,062,000 股，并于 2021 年 9 月 13 日在深圳证券交易所 创业板上市交易。首次公开发行前公司总股本为 352,455,000 股，首次公开发行 ...

国金证券股份有限公司（以下简称"保荐机构""国金证券"）作为上海兰 卫医学检验所股份有限公司（以下简称"兰卫医学""公司"）首次公开发行股 票并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳 证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》以及《深圳证券交易所上市公司自律监管指引第 2 号—— 创业板上市公司规范运作》等相关法律法规的要求，对兰卫医学首次公开发行前 已发行股份上市流通事项进行了核查，具体情况如下： 一、首次公开发行前已发行股份概况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意上海兰卫医学检验所股份有限公司首 次公开发行股票注册的批复》（证监许可〔2021〕2503 号）同意注册，公司向 社会公众公开发行人民币普通股（A 股）股票 48,062,000 股，并于 2021 年 9 月 13 日在深圳证券交易所创业板上市交易。首次公开发行前公司总股本为 352,455,000 股，首次公开发行完成后公司总股本为 400,517,000 股，其中无限售 条件流通股数量为 40,609,907 股，占发行后总股本的比例为 ...

证券代码：301060 证券简称：兰卫医学 公告编号：2024-041 上海兰卫医学检验所股份有限公司 关于股份回购进展情况的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 上海兰卫医学检验所股份有限公司（以下简称"公司"）第三届董事会第十八次会 议、第三届监事会第十六次会议审议通过了《关于回购公司股份方案的议案》。公司拟 使用自有资金通过深圳证券交易所股票交易系统以集中竞价交易方式回购公司部分人 民币普通股 A 股股份（以下简称"本次回购"），用于后期实施员工持股计划或股权激励 计划。本次回购的资金总额不低于人民币 1,500 万元（含），不超过人民币 3,000 万元 （含），回购股份的价格为不超过 21.09 元/股，不高于公司董事会通过回购决议前 30 个 交易日公司股票交易均价的 150%，回购股份的实施期限为自公司董事会审议通过回购 股份方案之日起 12 个月内。具体内容详见公司于 2023 年 11 月 16 日在巨潮资讯网披露 的《关于回购公司股份方案的公告》（公告编号：2023-056）及公司于 2023 年 11 月 20 日在巨潮资 ...

上海兰卫医学检验所股份有限公司 第三届董事会第二十二次会议决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、董事会会议召开情况 上海兰卫医学检验所股份有限公司（以下简称"公司"）第三届董事会第二十二次 会议于 2024 年 8 月 26 日在公司会议室以现场结合通讯会议方式召开。召开本次会议的 通知已于 2024 年 8 月 8 日以邮件形式通知全体董事。会议由公司董事长曾伟雄先生召 集和主持，本次会议应出席董事 9 人，实际出席董事 9 人。本次会议的召集、召开和表 决程序符合《中华人民共和国公司法》（以下简称"《公司法》"）和《上海兰卫医学 检验所股份有限公司章程》规定，会议合法、有效。 二、董事会会议审议情况 经与会董事认真审议，充分讨论，审慎表决，本次会议审议通过了以下议案： 1．审议通过《关于公司 2024 年半年度报告及其摘要的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《2024 年半年 度报告》（公告编号：2024-032）及《2024 年半年度报告摘要》（公告编号：2024-033）。 证 ...

Financial Performance - The company reported a half-year financial performance with a focus on accuracy and completeness, ensuring no misleading statements or omissions[2]. - The report period covers from January 1, 2024, to June 30, 2024, providing a clear timeframe for the financial data presented[6]. - The company's operating revenue for the reporting period was ¥888,219,074.60, representing a 6.00% increase compared to the same period last year[12]. - Net profit attributable to shareholders was ¥15,597,554.34, a significant increase of 955.77% from a loss of ¥1,822,631.04 in the previous year[12]. - The net profit after deducting non-recurring gains and losses was ¥10,912,127.51, up 190.36% from a loss of ¥12,076,096.59 in the same period last year[12]. - The company's basic and diluted earnings per share were both ¥0.0389, marking a 945.65% increase from a loss of ¥0.0046 per share in the previous year[12]. - The net cash flow from operating activities was -¥48,137,559.41, a decline of 134.74% compared to ¥138,583,813.28 in the previous year[12]. - Total assets at the end of the reporting period were ¥2,816,628,565.66, down 5.70% from ¥2,986,860,553.79 at the end of the previous year[12]. - The company's net assets attributable to shareholders increased slightly by 0.36% to ¥1,786,767,631.94 from ¥1,780,316,277.50 at the end of the previous year[12]. Corporate Governance - The company is listed on the Shenzhen Stock Exchange under the stock code 301060, highlighting its public trading status[7]. - The legal representative of the company is Zeng Weixiong, ensuring accountability in corporate governance[7]. - The company has a dedicated board secretary and securities representative, indicating a structured approach to investor relations[8]. - The company emphasizes the importance of risk awareness in its forward-looking statements, advising investors to understand the differences between plans, forecasts, and commitments[2]. - The company has maintained its registered address and contact information without changes during the reporting period, ensuring consistency in communication[9]. Risk Management - The financial report includes a detailed analysis of potential risks and countermeasures, which is crucial for investor awareness[2]. - The company faces innovation risks due to policy changes in the healthcare system, which may lead to market rule changes and regulatory risks in certain segments[58]. - The company is at risk of technological obsolescence in its R&D processes, which could hinder its ability to meet the demand for new diagnostic projects[59]. - The implementation of "volume-based procurement" policies may lead to significant price reductions in the procurement of diagnostic products, potentially impacting sales and profitability[60]. - The company acknowledges management risks associated with optimizing its business operations and the need for continuous improvement in management practices[66]. Research and Development - Research and development investment rose by 50.09% to ¥29.47 million, primarily due to key projects in digital slice standards[36]. - The company is focused on continuous innovation in pathology technology, with all major technical indicators of the AI diagnosis project achieved and several patents filed[19]. - The company has introduced advanced technologies such as single-cell sequencing and spatial transcriptomics to enhance research collaboration and clinical translation[18]. - The company has established a dedicated medical inspection technology expert team responsible for R&D in clinical medical testing, enhancing its position as a comprehensive technical service provider[26]. Market Position and Strategy - The company operates 13 independent testing laboratories across various cities, enhancing its service network in the medical diagnostics sector[16]. - The company is focused on optimizing laboratory layouts and expanding its services in pathology and molecular diagnostics, aiming to improve operational efficiency and service quality[17]. - The company has established five core service centers to support regional medical institutions, enhancing collaboration and resource sharing in medical diagnostics[17]. - The company has achieved a high market share and recognition in Hunan and Hubei provinces, becoming a comprehensive service provider in the medical testing industry[21]. - The company is actively upgrading strategic partnerships with major brands like Roche and Agilent to expand its in vitro diagnostic product platform business[20]. Financial Management - The company plans not to distribute cash dividends or issue bonus shares, indicating a focus on reinvestment[2]. - The company reported a significant increase in investment, with total investments during the reporting period reaching ¥179,851,761.30, a 316.12% increase from ¥43,220,701.87 in the same period last year[42]. - The total amount of raised funds was ¥13,902.18 million, with ¥279.81 million utilized during the reporting period, and a cumulative total of ¥11,918.73 million invested[45]. - The company has a restricted cash balance of ¥2,390,214.00 due to litigation freezes and guarantees[41]. - The company has reported a commitment to ensure the accuracy and completeness of the information in the prospectus, taking legal responsibility for any false statements or omissions[89]. Shareholder Relations - The company actively engages in protecting shareholder rights, particularly for minority shareholders, through various communication channels[75]. - The company emphasizes its commitment to environmental protection and sustainable development, adhering to national laws and regulations[74]. - The company has established a mechanism for fair and open communication with investors, ensuring their participation in significant corporate matters[75]. - The company has committed to a 36-month lock-up period for major shareholders, prohibiting the transfer of shares from the date of listing[82]. - Major shareholders are also subject to a 12-month lock-up period following the IPO, which has been fully complied with[82]. Compliance and Legal Matters - The company has not reported any administrative penalties related to environmental issues during the reporting period[74]. - The company has pending litigation with a total amount involved of 4,066.39 million yuan, with an estimated liability of 508.82 million yuan recognized[102]. - The company has incurred related party transactions totaling 185.82 million yuan, which is below the approved limit for 2024[104]. - The company has not engaged in any asset or equity acquisitions or sales during the reporting period[107]. - The company has not provided any guarantees that exceed 50% of its net assets during the reporting period[119]. Employee Relations - The company emphasizes employee welfare and engagement through various initiatives, fostering a supportive work environment and enhancing employee satisfaction[76]. - The company adheres to strict labor laws and regulations, ensuring timely payment of salaries and provision of social insurance for employees[76]. - The company promotes a culture of equality and non-discrimination in the workplace, ensuring a respectful and inclusive environment for all employees[76]. - The company has established a robust communication channel with employees to gather feedback and improve operational practices[76]. Environmental Responsibility - The company has implemented measures to promote low-carbon and environmentally friendly practices within its operations[74]. - The company does not belong to the category of key pollutant discharge units as defined by environmental protection authorities[74]. - The company actively participates in local government poverty alleviation and rural revitalization programs, providing technical support and resources to improve healthcare services in remote areas[79]. - A remote pathology diagnosis platform was established in cooperation with local hospitals, significantly improving medical diagnostic services in remote regions and reducing patient burdens[80]. Financial Reporting and Audit - The half-year financial report has not been audited[100]. - The company’s financial report for the first half of 2024 has not been audited[137]. - The financial statements are prepared based on the enterprise accounting standards and reflect the company's financial position accurately[168]. - The company has not reported any new strategies or market expansions in the current financial period[158].

| 非经营性资金占用 | 资金占用方名称 | 占用方与上市公 | 上市公司核算的会 | 2024 年初往来资金 | 2024 年 1-6 月占用 累计发生金额（不 | 2024 年 1-6 月占用资 | 2024 年 1-6 月偿还 | 2024 年 6 月末往来 | 占用形成 | 占用性质 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 司的关联关系 | 计科目 | 余额 | 含利息） | 金的利息（如有） | 累计发生金额 | 资金余额 | 原因 | | | 控股股东、实际控制 人及其附属企业 | 无 | 不适用 | 不适用 | | | | | - | | 不适用 | | 小计 | — | — | — | - | - | - | - | - | | | | 前控股股东、实际控 | 无 | 不适用 | 不适用 | | | | | - | | 不适用 | | 制人及其附属企业 | | | | | | | | | | | | 小计 | — | — | — | - | - | - | - | - | | | | ...

关于 2024 年半年度募集资金存放与使用情况的专项报告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 根据深圳证券交易所《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》及《深圳证券交易所创业板上市公司自律监管指南第 2 号——公告格 式》的规定，将上海兰卫医学检验所股份有限公司（以下简称"公司"）2024 年 1-6 月 募集资金存放与使用情况报告如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 证券代码：301060 证券简称：兰卫医学 公告编号：2024-038 上海兰卫医学检验所股份有限公司 金账户 25.90 万元；截至 2024 年 6 月 30 日，募集资金专户余额合计为 2,076.25 万元。 二、募集资金存放和管理情况 根据有关法律法规的规定，遵循规范、安全、高效、透明的原则，公司制定了《募 集资金管理办法》，对募集资金的存储、审批、使用、管理与监督做出了明确的规定， 以在制度上保证募集资金的规范使用。 2021 年 9 月，公司与招商银行股份有限公司上海淮海支行（以下简称"招行上海 淮海支行 ...

| 项 目 | 工作内容 | | --- | --- | | （3）列席公司监事会次数 | 未现场列席，已审阅会议文件 | | 5.现场检查情况 | | | （1）现场检查次数 | 0 次 | | （2）现场检查报告是否按照本所规定报送 | 不适用 | | （3）现场检查发现的主要问题及整改情况 | 不适用 | | 发表专项意见情况 6. | | | （1）发表专项意见次数 | 次 4 | | （2）发表非同意意见所涉问题及结论意见 | 无 | | 7.向本所报告情况（现场检查报告除外） | | | （1）向本所报告的次数 | 次 0 | | （2）报告事项的主要内容 | 不适用 | | （3）报告事项的进展或者整改情况 | 不适用 | | 8．关注职责的履行情况 | | | （1）是否存在需要关注的事项 | 否 | | （2）关注事项的主要内容 | 不适用 | | （3）关注事项的进展或者整改情况 | 不适用 | | 9.保荐业务工作底稿记录、保管是否合规 | 是 | | 10.对上市公司培训情况 | | | （1）培训次数 | 次 0 | | （2）培训日期 | 不适用 | | （3）培训的主要内容 | ...

证券代码：301060 证券简称：兰卫医学 公告编号：2024-035 上海兰卫医学检验所股份有限公司 第三届监事会第十九次会议决议公告 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海兰卫医学检验所股份有限公司（以下简称"公司"）第三届监事会第十九次会 议于 2024 年 8 月 26 日在公司会议室以现场结合通讯会议方式召开。召开本次会议的通 知已于 2024 年 8 月 8 日以邮件形式通知全体监事。会议由公司由监事会主席刘国权先 生召集和主持，本次会议应出席监事 3 人，实际出席监事 3 人。本次会议的召集、召开 和表决程序符合《中华人民共和国公司法》和《上海兰卫医学检验所股份有限公司章程》 规定，会议合法、有效。 二、监事会会议审议情况 经与会监事认真审议，充分讨论，审慎表决，本次会议审议通过了以下议案： 1．审议通过《关于公司 2024 年半年度报告及其摘要的议案》 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）上的《2024 年半年 度报告》（公告编号：2024-032）及《2024 年半年 ...